Log in
NASDAQ:GLPG

GALAPAGOS NV/S Stock Forecast, Price & News

$139.27
-1.84 (-1.30 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$138.05
Now: $139.27
$140.29
50-Day Range
$122.47
MA: $155.62
$193.83
52-Week Range
$112.00
Now: $139.27
$274.03
Volume95,190 shs
Average Volume155,751 shs
Market Capitalization$9.09 billion
P/E Ratio89.28
Dividend YieldN/A
Beta0.94
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Read More
GALAPAGOS NV/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLPG
CUSIPN/A
Phone321-534-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.00 billion
Cash Flow$6.36 per share
Book Value$58.75 per share

Profitability

Net Income$167.83 million

Miscellaneous

Employees1,003
Market Cap$9.09 billion
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$139.27
-1.84 (-1.30 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions

How has GALAPAGOS NV/S's stock been impacted by Coronavirus (COVID-19)?

GALAPAGOS NV/S's stock was trading at $186.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GLPG shares have decreased by 25.1% and is now trading at $139.27.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of GALAPAGOS NV/S?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for GALAPAGOS NV/S
.

When is GALAPAGOS NV/S's next earnings date?

GALAPAGOS NV/S is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for GALAPAGOS NV/S
.

How were GALAPAGOS NV/S's earnings last quarter?

GALAPAGOS NV/S (NASDAQ:GLPG) released its earnings results on Thursday, August, 6th. The biotechnology company reported ($1.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by $0.88. The biotechnology company had revenue of $129.53 million for the quarter, compared to analysts' expectations of $118.41 million. GALAPAGOS NV/S had a net margin of 8.13% and a return on equity of 8.24%.
View GALAPAGOS NV/S's earnings history
.

What price target have analysts set for GLPG?

14 Wall Street analysts have issued twelve-month price targets for GALAPAGOS NV/S's stock. Their forecasts range from $123.00 to $290.00. On average, they anticipate GALAPAGOS NV/S's stock price to reach $187.75 in the next year. This suggests a possible upside of 34.8% from the stock's current price.
View analysts' price targets for GALAPAGOS NV/S
.

Who are some of GALAPAGOS NV/S's key competitors?

What other stocks do shareholders of GALAPAGOS NV/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Pharming Group (PHGUF), Biogen (BIIB), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

Who are GALAPAGOS NV/S's key executives?

GALAPAGOS NV/S's management team includes the following people:
  • Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)
  • Mr. Bart Filius MBA, CFO & COO (Age 49)
  • Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)
  • Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
  • Dr. Andre Hoekema, Chief Bus. Officer (Age 62)

When did GALAPAGOS NV/S IPO?

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is GALAPAGOS NV/S's stock symbol?

GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."

Who are GALAPAGOS NV/S's major shareholders?

GALAPAGOS NV/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (2.18%), FMR LLC (1.57%), Cormorant Asset Management LP (0.15%), Alberta Investment Management Corp (0.12%), Public Employees Retirement Association of Colorado (0.08%) and Envestnet Asset Management Inc. (0.07%).

Which major investors are selling GALAPAGOS NV/S stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of America Corp DE, Peregrine Capital Management LLC, Goldman Sachs Group Inc., Eqis Capital Management Inc., Pinnacle Associates Ltd., Dorsey Wright & Associates, and Sei Investments Co..

Which major investors are buying GALAPAGOS NV/S stock?

GLPG stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Alberta Investment Management Corp, Marshall Wace North America L.P., Aigen Investment Management LP, Public Employees Retirement Association of Colorado, ETRADE Capital Management LLC, Bank of New York Mellon Corp, and Marshall Wace LLP.

How do I buy shares of GALAPAGOS NV/S?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GALAPAGOS NV/S's stock price today?

One share of GLPG stock can currently be purchased for approximately $139.27.

How big of a company is GALAPAGOS NV/S?

GALAPAGOS NV/S has a market capitalization of $9.09 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis. GALAPAGOS NV/S employs 1,003 workers across the globe.

What is GALAPAGOS NV/S's official website?

The official website for GALAPAGOS NV/S is www.glpg.com.

How can I contact GALAPAGOS NV/S?

GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.